Metabolite Profiling and Analysis

Comprehensive Metabolite Profiling and Analysis Services – From Untargeted Discovery to Targeted Quantification and Mechanistic Interpretation

The comprehensive analysis of metabolites – the small‑molecule intermediates and end‑products of cellular metabolism – has become a cornerstone of systems biology, biomarker discovery, pharmaceutical development, and precision medicine. Metabolite profiling provides a direct functional readout of the physiological state of a biological system, reflecting the integrated response of genes, proteins, and environmental factors. Whether the goal is to identify novel biomarkers for disease, to elucidate the mechanism of action of a drug, to monitor the quality of a biopharmaceutical production process, or to characterise the metabolic impact of a genetic modification, reliable metabolite analysis is essential. However, a successful metabolomics study is not merely a matter of running a single analytical platform; it requires a carefully designed experimental strategy, robust sample preparation, orthogonal analytical techniques (LC‑MS, GC‑MS, NMR), rigorous data processing, and, most importantly, informed biological interpretation. The choice of method – whether untargeted (discovery) or targeted (quantitative) metabolomics, and the selection of the appropriate separation and detection technologies – must be tailored to the sample matrix, the metabolic questions, and the required sensitivity and throughput. A poorly designed workflow can lead to missed metabolites, biased quantification, and misleading biological conclusions. Our ISO/IEC 17025‑accredited and GMP‑compliant laboratory offers a fully integrated metabolite analysis platform, encompassing the entire spectrum from sample collection and preparation to high‑resolution mass spectrometry and NMR‑based profiling, coupled with advanced bioinformatics and pathway analysis. We deliver quantitative, traceable data, comprehensive identification of metabolites, and expert biological interpretation, enabling you to uncover meaningful metabolic insights for research, development, or clinical applications.

1. The Scientific and Regulatory Rationale for Rigorous Metabolite Analysis

Metabolite analysis serves multiple critical purposes: (a) biomarker discovery and validation – identifying metabolites that distinguish between healthy and diseased states or that predict treatment response; (b) mechanistic pharmacology and toxicology – understanding the metabolic pathways affected by drugs or toxins; (c) quality control of biopharmaceuticals and food products – monitoring metabolite profiles to ensure product consistency and safety; (d) metabolic engineering – characterising the metabolic network of genetically modified organisms; (e) nutritional and environmental metabolomics – assessing the impact of diet or environmental exposures; and (f) clinical diagnostics – using metabolite panels for early disease detection. The choice of analytical platform – whether liquid chromatography‑mass spectrometry (LC‑MS), gas chromatography‑mass spectrometry (GC‑MS), capillary electrophoresis‑mass spectrometry (CE‑MS), or nuclear magnetic resonance (NMR) spectroscopy – must be guided by the chemical diversity of the metabolites of interest, the required sensitivity, and the need for absolute quantification. Regulatory guidelines, such as FDA guidance on biomarker qualification and ICH M10 on bioanalytical method validation, require rigorous method validation, including assessment of selectivity, sensitivity, linearity, precision, accuracy, and stability. Our service begins with a comprehensive consultation to define the optimal metabolite analysis strategy, ensuring that the data are scientifically robust, and that the method is fully compliant with the relevant regulatory and quality standards.

2. Our Comprehensive Metabolite Analysis Platform – Multi‑Technology, Multi‑Matrix

We maintain a complete suite of validated metabolite analysis workflows, all performed in a dedicated analytical facility with stringent quality controls, and using certified reference materials and stable isotope‑labelled internal standards for accurate quantification. Our portfolio includes:

2.1 Untargeted Metabolomics – High‑Resolution LC‑MS and GC‑MS
We perform untargeted metabolomics using high‑resolution mass spectrometry (Q‑TOF, Orbitrap) coupled with ultra‑high‑performance liquid chromatography (UHPLC) or gas chromatography (GC). We employ both reversed‑phase and hydrophilic interaction (HILIC) chromatography to cover a broad spectrum of polar and non‑polar metabolites. Our data acquisition uses data‑independent acquisition (DIA) or data‑dependent acquisition (DDA) for comprehensive coverage. We process the raw data using advanced software (e.g., XCMS, MZmine, Compound Discoverer) for peak detection, alignment, and feature extraction. We then perform statistical analysis (PCA, PLS‑DA, OPLS‑DA) to identify discriminating metabolites, and we use accurate mass, MS/MS fragmentation, and database searching (HMDB, METLIN, KEGG) for tentative identification. We provide a complete list of significantly altered metabolites, with their m/z, retention time, tentative identity, and fold change.

2.2 Targeted Quantitative Metabolomics – Absolute Quantification with Stable Isotope Dilution
For absolute quantification of specific metabolites, we develop and validate targeted LC‑MS/MS or GC‑MS/MS methods using stable isotope‑labelled internal standards (SIL‑IS). We quantify a wide range of metabolite classes, including amino acids, organic acids, fatty acids, nucleotides, sugars, and bile acids. We validate each method according to FDA/EMA guidelines, demonstrating selectivity, linearity, accuracy (spike‑recovery), precision, and stability. We provide results in absolute concentrations (e.g., µM, ng/mL) with detailed quality control data. We can design custom panels of up to 100‑200 metabolites in a single run, with high sensitivity (sub‑ng/mL) and wide dynamic range (up to 4 orders of magnitude).

2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy – Structural Elucidation and Quantitative Profiling
We use high‑field NMR (600‑800 MHz) for metabolite profiling and structural identification. NMR offers excellent reproducibility, non‑destructive analysis, and the ability to identify unknown metabolites. We perform both 1D (¹H, ¹³C) and 2D (COSY, TOCSY, HSQC, HMBC) NMR experiments for structural elucidation. We use targeted and untargeted profiling for biofluids (serum, urine, CSF), tissue extracts, and cell culture supernatants. We provide quantitative data (via electronic reference to access in‑vivo concentrations, ERETIC) and structural assignments for unknowns, with a spectral library of over 500 metabolites.

2.4 Lipidomics – Comprehensive Characterisation of Lipid Species
We offer untargeted and targeted lipidomics using UHPLC‑MS/MS (with both positive and negative ionisation modes) to characterise over 1,500 lipid species across multiple classes: glycerophospholipids, sphingolipids, glycerolipids, sterols, and fatty acids. We use lipid‑specific databases and software (e.g., LipidBlast, LIPID MAPS) for identification and quantification. We provide the lipid class, fatty acyl composition, and relative or absolute concentrations.

2.5 Metabolic Flux Analysis – Stable Isotope Tracing (¹³C, ¹⁵N, ²H)
We perform stable isotope tracer studies using ¹³C‑labelled substrates (e.g., ¹³C‑glucose, ¹³C‑glutamine) to determine metabolic pathway activity and flux rates. We analyse the labelling patterns of metabolites by LC‑MS/MS and GC‑MS, and we use mathematical modelling (e.g., with INCA or OpenFLUX) to quantify pathway fluxes. This service is essential for metabolic engineering and for studying pathway dynamics under different conditions.

2.6 Sample Preparation and Pre‑Analytical Optimisation – The Foundation of Reliable Data
We optimise and validate sample preparation protocols for each sample type (biofluids, tissues, cells, culture media, food, environmental samples). We use standardised procedures: protein precipitation, liquid‑liquid extraction, solid‑phase extraction, and derivatisation (for GC‑MS). We incorporate internal standards at the earliest possible step to correct for recovery and matrix effects. We also assess the stability of metabolites under different storage and handling conditions.

2.7 Data Processing, Statistical Analysis, and Pathway Interpretation
We provide comprehensive bioinformatics services, including data normalisation (e.g., to total ion count or to an internal standard), missing value imputation, and univariate and multivariate statistics. We perform pathway enrichment analysis (using MetaboAnalyst, KEGG, or Reactome) to identify the biological pathways most affected by the experimental conditions. We also integrate metabolomics data with transcriptomics or proteomics for a multi‑omics perspective.

3. Advanced Capabilities – Mechanistic Deep‑Dive, Custom Panels, and Regulatory Support

For clients requiring a deeper level of characterisation or a high‑level validation of their metabolomics workflow, we offer a suite of customised, research‑grade services that go beyond routine profiling:

3.1 Compound Identification – Multi‑Stage MS/MS, Ion Mobility, and Database Matching
We use multi‑stage mass spectrometry (MS³) and ion mobility spectrometry to improve the confidence of metabolite identification. We also perform manual interpretation of MS/MS spectra and use multiple databases (HMDB, METLIN, MassBank, GNPS). For critical unknowns, we can perform chemical synthesis or isolate the metabolite for NMR confirmation.

3.2 Chemical Isotope Labelling (CIL) – For Enhanced Coverage of Polar Metabolites
We use chemical isotope labelling (e.g., ¹²C/¹³C‑dansyl labelling for amines and phenols) to improve the detection and quantification of polar metabolites that are difficult to detect by conventional LC‑MS. This method increases sensitivity and enables relative quantification between samples.

3.3 Metabolite Profiling for Bioprocess Monitoring – Real‑Time and At‑Line Analysis
We provide rapid metabolite profiling for biopharmaceutical production, using high‑throughput LC‑MS and automated sampling to monitor the concentration of nutrients, by‑products, and product‑related metabolites in cell culture media. We can also perform chemometric modelling to predict process outcomes and to optimise feed strategies.

3.4 Method Validation and Regulatory Submission Support
We provide full method validation for targeted metabolomics assays, including: (a) selectivity (no interference from matrix); (b) linearity (over the expected concentration range); (c) accuracy (by spike‑recovery); (d) precision (intra‑assay and inter‑assay); (e) limit of detection (LOD) and limit of quantification (LOQ); (f) matrix effect (by post‑column infusion or by comparing standards in solvent vs. matrix); (g) stability (bench‑top, freeze‑thaw, long‑term). The validation report is structured to meet the requirements of the FDA, EMA, or ICH M10.

3.5 Integration with Other Omics – Multi‑Omic Correlation
We offer integrated multi‑omics analysis, combining metabolomics with transcriptomics (RNA‑seq) and proteomics. We use correlation analysis (Spearman, Pearson), network analysis (e.g., WGCNA), and pathway‑level integration (e.g., with PathVisio) to identify the key molecular drivers of the observed phenotype.

4. Data Integrity, Standardisation, and Comprehensive Reporting

All analyses are conducted under a strict quality management system that includes the use of certified reference materials, routine system suitability tests, and participation in proficiency testing schemes (e.g., NIST, or the Metabolomics Quality Assurance and Quality Control Consortium). Our reports provide:

• Full method description – including sample preparation, chromatographic conditions, mass spectrometric settings, and data processing parameters.
• Detailed results – including the identified metabolites (with retention times, m/z, MS/MS fragments), relative or absolute concentrations, statistical significance (p‑values, fold changes), and quality control metrics (QC sample reproducibility, IS recovery).
• Pathway and enrichment analysis – highlighting the most affected metabolic pathways, with graphical representations (heatmaps, volcano plots, pathway maps).
• Validation data – for targeted assays, including the linearity, precision, accuracy, LOD, LOQ, and matrix effect results.
• Interpretative comments – by our expert metabolomics scientists, providing a biological context and actionable recommendations.

Our reports are authored by senior metabolomics scientists and bioinformaticians who provide not just raw data, but insightful interpretation to guide your research, development, or clinical decisions.

Turnaround times: 2‑3 weeks for untargeted metabolomics, 1‑2 weeks for targeted panels, and 3‑4 weeks for flux analysis and integrated multi‑omics. Express services are available for urgent projects.

5. Our Unmatched Expertise – Why Choose Our Laboratory for Metabolite Analysis

We are one of the few laboratories that hold ISO/IEC 17025 accreditation and GMP compliance for the full spectrum of metabolite analysis methods, including untargeted and targeted LC‑MS, GC‑MS, NMR, and lipidomics. Our integrated infrastructure combines state‑of‑the‑art high‑resolution mass spectrometers, NMR instruments, and a dedicated bioinformatics cluster – enabling cross‑platform validation and a comprehensive view of the metabolome. Our team comprises PhD‑level analytical chemists, biochemists, bioinformaticians, and pharmacologists with extensive experience in method development, validation, and regulatory submissions, and we have a proven track record of supporting academic research, pharmaceutical R&D, and clinical biomarker studies.

We offer unparalleled flexibility: we accept a wide range of matrices – biofluids, tissues, cells, culture media, food, and environmental samples – and we provide customised workflows to address your specific metabolic questions. Our secure online portal enables real‑time tracking, access to raw data, and downloadable reports.

Our modular pricing ensures cost‑effectiveness: you select the level of analysis – from a simple targeted panel to a full untargeted profiling plus flux analysis – with discounts for routine monitoring programmes and bulk submissions. We also provide training, method transfer, and technical consultancy to help you build or strengthen your internal metabolomics capabilities.

With a proven history of serving over 90 clients in the pharmaceutical, biotechnology, clinical research, and food industries, we have enabled our partners to discover novel biomarkers, understand drug mechanisms, optimise bioprocesses, and accelerate product development. We invite you to leverage our expertise for your metabolite analysis needs.

Contact our technical experts today to discuss your sample types, target metabolites, and specific research or regulatory goals. We will design a tailored testing plan and provide a detailed proposal within one business day.